{"transactions":[{"id":736160,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-16T20:18:43.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":11389,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":11389,"derivative":{"exercise_price":49.56,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":11389},"source":{"system":"sec-edgar","filing":"0001935943-26-000002","document":"wk-form4_1781641121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000193594326000002/wk-form4_1781641121.xml","form_type":"4"}},{"id":736159,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:18:43.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":2265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":6856,"source":{"system":"sec-edgar","filing":"0001935943-26-000002","document":"wk-form4_1781641121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000193594326000002/wk-form4_1781641121.xml","form_type":"4"}},{"id":1109754,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-16T22:07:16.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":15372,"derivative":{"exercise_price":34.46,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15372},"source":{"system":"sec-edgar","filing":"0001935943-25-000004","document":"wk-form4_1750111630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000193594325000004/wk-form4_1750111630.xml","form_type":"4"}},{"id":1109753,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T22:07:16.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":3041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":4591,"source":{"system":"sec-edgar","filing":"0001935943-25-000004","document":"wk-form4_1750111630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000193594325000004/wk-form4_1750111630.xml","form_type":"4"}},{"id":1403235,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T16:15:15.000Z","date":"2024-09-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":5.35,"expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-107793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000095017024107793/ownership.xml","form_type":"4"}},{"id":1403234,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T16:15:15.000Z","date":"2024-09-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":2.83,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-107793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000095017024107793/ownership.xml","form_type":"4"}},{"id":1403233,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T16:15:15.000Z","date":"2024-09-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each \"Stock Option\") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option."}],"balance_after":0,"derivative":{"exercise_price":2.99,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-107793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000095017024107793/ownership.xml","form_type":"4"}},{"id":1403232,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T16:15:15.000Z","date":"2024-09-18","kind":"other","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-107793","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000095017024107793/ownership.xml","form_type":"4"}},{"id":1403231,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T16:15:15.000Z","date":"2024-09-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab (\"Parent\"), and Genesis Merger Sub, Inc. (\"Purchaser\"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the \"Merger\"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the \"Merger Consideration\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab (\"Parent\"), and Genesis Merger Sub, Inc. (\"Purchaser\"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the \"Merger\"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued form footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950170-24-107793","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000095017024107793/ownership.xml","form_type":"4"}},{"id":1478555,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-14T16:40:25.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director."}],"balance_after":30000,"derivative":{"exercise_price":2.99,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-24-005080","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218024005080/primarydocument.xml","form_type":"4"}},{"id":1478554,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T16:40:25.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents (i) 10,000 RSUs from award granted on June 15, 2023; and (ii) 10,000 RSUs from award granted on June 13, 2024."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001562180-24-005080","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218024005080/primarydocument.xml","form_type":"4"}},{"id":1484892,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:12:18.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":7250,"derivative":{"exercise_price":72.51,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0001649094-24-000015","document":"wk-form4_1718050330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000015/wk-form4_1718050330.xml","form_type":"4"}},{"id":1484891,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-10T20:12:18.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":1550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date."}],"balance_after":1550,"source":{"system":"sec-edgar","filing":"0001649094-24-000015","document":"wk-form4_1718050330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000015/wk-form4_1718050330.xml","form_type":"4"}},{"id":1727642,"issuer":{"id":1164,"kind":"organization","name":"Vaxcyte, Inc.","symbol":"PCVX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-29T21:49:16.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option shall vest over 36 months, 1/3 of which will vest on November 27, 2024 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date."}],"balance_after":30000,"derivative":{"exercise_price":50.13,"expiration_date":"2033-11-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-056913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649094/000120919123056913/doc4.xml","form_type":"4"}},{"id":1851492,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-06-16T16:06:53.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director."}],"balance_after":30000,"derivative":{"exercise_price":2.83,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-23-005268","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023005268/primarydocument.xml","form_type":"4"}},{"id":1851491,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T16:06:53.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001562180-23-005268","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218023005268/primarydocument.xml","form_type":"4"}},{"id":2219195,"issuer":{"id":87413,"kind":"organization","name":"G1 Therapeutics, Inc.","symbol":"GTHX"},"owners":[{"id":37685,"kind":"person","name":"Lee Jacks","position":1,"cik":"0001935943","reported_name":"Lee Jacks","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2022-06-29T17:56:07.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in 36 equal monthly installments beginning on June 30, 2022, subject to the Reporting Person's continued service through each applicable vesting date."}],"balance_after":60000,"derivative":{"exercise_price":5.35,"expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001562180-22-005393","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1560241/000156218022005393/primarydocument.xml","form_type":"4"}}]}